News from abbvie A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 22, 2015, 08:00 ET

AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics

AbbVie (NYSE: ABBV) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie's purchase of...

May 21, 2015, 08:00 ET

AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics

 AbbVie (NYSE: ABBV) announced today the per share offer consideration amounts pursuant to its previously announced offer to acquire each...

May 20, 2015, 15:17 ET

Sociedade Brasileira de Reumatologia faz alerta na Semana de Combate a Espondilite Anquilosante

A partir desta segunda quinzena de maio, a Sociedade Brasileira de Reumatologia (SBR) vai a público com campanha de esclarecimento para a...

May 15, 2015, 16:43 ET

AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.

 AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to...

May 15, 2015, 09:44 ET

AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS)

 AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation...

May 13, 2015, 08:15 ET

AbbVie to Present at UBS Global Healthcare Conference

 AbbVie (NYSE: ABBV) will participate in the UBS Global Healthcare Conference on Wednesday, May 20, 2015. Bill Chase, executive vice president...

May 12, 2015, 08:02 ET

AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015

 AbbVie (NYSE: ABBV) announced that 18 abstracts in its gastroenterology and hepatology programs will be presented at Digestive Disease...

May 11, 2015, 08:00 ET

AbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the 51st American Society of Clinical Oncology Annual Meeting

AbbVie (NYSE: ABBV) announced 17 abstracts from studies of the company's oncology pipeline are being presented at the 51st Annual Meeting of the...

May 06, 2015, 07:30 ET

Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation in Relapsed or Refractory Chronic Lymphocytic Leukemia in Previously Treated Patients with the 17p Deletion Genetic Mutation

AbbVie (NYSE: ABBV) today announced its investigational medicine venetoclax, an inhibitor of the B-cell lymphoma-2 (BCL-2) protein that is being...

May 06, 2015, 07:00 ET

AbbVie to Present at Bank of America Merrill Lynch 2015 Health Care Conference

AbbVie (NYSE: ABBV) will participate in the Bank of America Merrill Lynch 2015 Health Care Conference on Wednesday, May 13, 2015. Richard A....

May 05, 2015, 12:20 ET

AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy and Safety of HUMIRA® (adalimumab) in Patients with Non-Infectious Intermediate, Posterior, or Panuveitis

AbbVie (NYSE: ABBV) announced results from VISUAL‑I, a Phase 3 study investigating the efficacy and safety of HUMIRA® (adalimumab) in...

May 01, 2015, 16:59 ET

AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.

 AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to...

Apr 29, 2015, 08:00 ET

AbbVie to Present at Deutsche Bank 40th Annual Health Care Conference

 AbbVie (NYSE: ABBV) will participate in the Deutsche Bank 40th Annual Health Care Conference on Wednesday, May 6, 2015. Bill Chase, executive...

Apr 25, 2015, 10:00 ET

AbbVie Presents Late-Breaking, Preliminary Phase 3b Data with VIEKIRAX® + EXVIERA® in Chronic Hepatitis C Patients with Renal Impairment at The International Liver Congress™ 2015

AbbVie (NYSE: ABBV) today announced new, preliminary safety and efficacy data from the first cohort of its ongoing, Phase 3b RUBY-I study. RUBY-I...

Apr 24, 2015, 00:45 ET

U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C

 AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted...

Apr 23, 2015, 15:28 ET

Anvisa aprova VIEKIRA PAK, da AbbVie, para o tratamento de pacientes brasileiros com Hepatite C crônica, Genótipo 1

A Anvisa (Agência Nacional de Vigilância Sanitária) aprovou, em processo de análise prioritária, VIEKIRA PAK (comprimidos...

Apr 23, 2015, 07:48 ET

AbbVie Reports First-Quarter 2015 Financial Results

 AbbVie (NYSE: ABBV) announced financial results for the first quarter ended March 31, 2015. "AbbVie had an exceptional first quarter,...

Apr 17, 2015, 16:47 ET

AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.

 AbbVie Inc. ("AbbVie") (NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to...

Apr 15, 2015, 19:00 ET

AbbVie's Investigational Chronic Hepatitis C Treatment Granted Priority Review in Japan

 AbbVie (NYSE: ABBV) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted priority review for its...

Apr 15, 2015, 10:05 ET

AbbVie to Host First-Quarter Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2015 financial results on Thursday, April 23, 2015, before the market opens. AbbVie will host...